Hyperlipidemia and Allograft Rejection.

Area of Science:

• Immunology
• Transplantation Science
• Metabolic Disorders

Background:

• Improved immunosuppression enhances short-term organ transplant survival.
• Long-term graft dysfunction remains a significant challenge.
• Comorbidities, like hyperlipidemia, increasingly recognized as factors affecting graft survival.

Purpose of the Study:

• To review recent advances in understanding how lipid alterations impact immune function and graft survival.
• To explore the role of hyperlipidemia as a comorbidity in organ transplantation.
• To summarize the effects of altered lipids on immune responses to allografts.

Main Methods:

• Review of recent scientific literature on lipid metabolism and immune function in transplantation.
• Analysis of findings from human studies and mouse models.
• Synthesis of evidence linking hyperlipidemia to immune cell alterations and graft rejection.

Main Results:

• Controlling low-density lipoprotein (LDL) levels is vital in transplant recipients to reduce chronic allograft vasculopathy (CAV).
• Elevated cholesterol levels induce significant immune system changes, affecting T cell proliferation, differentiation, and suppression.
• Hyperlipidemia in animal models demonstrates altered B cell subsets and antigen-presenting cell function, potentially increasing rejection.

Conclusions:

• Cholesterol metabolism is essential for immune cell homeostasis and activation.
• Elevated serum cholesterol profoundly impacts the immune system, as evidenced by human and mouse studies.
• Hyperlipidemia accelerates graft rejection by increasing T cell activation, altering T helper subsets, and enhancing antigen-presenting cell inflammatory capacity.